Literature DB >> 10078880

Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine.

D J Doudet1, G L Chan, S Jivan, O T DeJesus, E G McGeer, C English, T J Ruth, J E Holden.   

Abstract

The effectiveness of 6-[18F]fluoro-L-m-tyrosine (6FMT) to evaluate dopamine presynaptic integrity was compared to that of 6-[18F]fluoro-L-dopa (6FDOPA) in vivo by positron emission tomography (PET). Six normal and six 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys received 6FDOPA and 6FMT PET scans on separate occasions with identical scanning protocols. Four measures, the rate of uptake of tracer into striatum using either the arterial input function (Ki) or the activity in the occipital cortex as the input function (Kc), the rate of loss of striatal radioactivity (k(loss)), and an index of "effective turnover" of dopamine (k(loss)/Ki), were obtained for both tracers during extended PET studies. 6-[18F]Fluoro-L-m-tyrosine was as effective as 6FDOPA in separating normals from MPTP-lesioned subjects on the basis of the uptake rate constants Ki and Kc. However, in contrast to 6FDOPA, it was not possible to differentiate the normal from the lesioned animal using k(loss) or k(loss)/Ki for 6FMT. Thus, FMT appears to be a reasonable, highly specific tracer for studying the activity of aromatic dopa decarboxylase enzyme as an index of presynaptic integrity. However, if one is interested in investigating further the metabolic pathway and obtaining an in vivo estimate of the effective turnover of dopamine (after pharmacologic manipulation, for example), 6FDOPA remains the tracer of choice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10078880     DOI: 10.1097/00004647-199903000-00006

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  11 in total

1.  A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.

Authors:  Catherine L Gallagher; Bradley T Christian; James E Holden; Onofre T Dejesus; Robert J Nickles; Laura Buyan-Dent; Barbara B Bendlin; Sandra J Harding; Charles K Stone; Barb Mueller; Sterling C Johnson
Journal:  Mov Disord       Date:  2011-06-02       Impact factor: 10.338

2.  Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease.

Authors:  Navin Maswood; Jennifer Young; Edward Tilmont; Zhiming Zhang; Don M Gash; Greg A Gerhardt; Richard Grondin; George S Roth; Julie Mattison; Mark A Lane; Richard E Carson; Robert M Cohen; Peter R Mouton; Christopher Quigley; Mark P Mattson; Donald K Ingram
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-16       Impact factor: 11.205

3.  PET imaging in rats to discern temporal onset differences between 6-hydroxydopamine and tau gene vector neurodegeneration models.

Authors:  Ronald L Klein; Robert D Dayton; Tracee L Terry; Chris Vascoe; John J Sunderland; Kerrie H Tainter
Journal:  Brain Res       Date:  2009-02-10       Impact factor: 3.252

4.  Subregional 6-[18F]fluoro-ʟ-m-tyrosine uptake in the striatum in Parkinson's disease.

Authors:  Sayaka Asari; Ken-ichi Fujimoto; Akihiro Miyauchi; Toshihiko Sato; Imaharu Nakano; Shin-ichi Muramatsu
Journal:  BMC Neurol       Date:  2011-03-23       Impact factor: 2.474

5.  Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats.

Authors:  Agnieszka Ciesielska; Nitasha Sharma; Janine Beyer; John Forsayeth; Krystof Bankiewicz
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

6.  Preliminary evidence of increased striatal dopamine in a nonhuman primate model of maternal immune activation.

Authors:  Melissa D Bauman; Tyler A Lesh; Douglas J Rowland; Cynthia M Schumann; Jason Smucny; David L Kukis; Simon R Cherry; A Kimberley McAllister; Cameron S Carter
Journal:  Transl Psychiatry       Date:  2019-04-12       Impact factor: 6.222

7.  PET 6-[F]fluoro-L-m-tyrosine Studies of Dopaminergic Function in Human and Nonhuman Primates.

Authors:  Jamie L Eberling; Krystof S Bankiewicz; James P O'Neil; William J Jagust
Journal:  Front Hum Neurosci       Date:  2008-03-28       Impact factor: 3.169

8.  Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications.

Authors:  Massimo S Fiandaca; Krystof S Bankiewicz; Howard J Federoff
Journal:  Pharmaceuticals (Basel)       Date:  2012-06-04

9.  Freezing of Gait in Parkinson's Disease Is Associated with Reduced 6-[(18)F]Fluoro-l-m-tyrosine Uptake in the Locus Coeruleus.

Authors:  Sayaka Asari Ono; Toshihiko Sato; Shin-Ichi Muramatsu
Journal:  Parkinsons Dis       Date:  2016-02-23

10.  The cognitive effects of a promised bonus do not depend on dopamine synthesis capacity.

Authors:  Lieke Hofmans; Ruben van den Bosch; Jessica I Määttä; Robbert-Jan Verkes; Esther Aarts; Roshan Cools
Journal:  Sci Rep       Date:  2020-10-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.